Prelude Therapeutics Incorporated (PRLD)Healthcare | Biotechnology | Wilmington, United States | NasdaqGS
4.44 USD
-0.37
(-7.596%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.40 -0.04 (-0.040%) ⇩ (July 13, 2026, 4:36 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:04 a.m. EDT
The investment case here is structurally broken. While the stock recently rallied 12% and beat earnings estimates, the underlying business is in freefall, having lost 97% of its value over the last four years with four consecutive years of negative annual returns. The company is burning cash aggressively, reporting negative operating cash flow and negative free cash flow, while holding no dividend to cushion the blow. The recent price surge appears to be a speculative reaction to a single earnings beat or analyst initiation, but the market's long-term verdict remains severe: the business is deteriorating rapidly. Options traders are clearly hedging against further downside, placing massive protection at lower strikes rather than betting on a recovery. This is a high-risk speculative vehicle with no fundamental safety margin. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.074163 |
| AutoETS | 0.074163 |
| MSTL | 0.076075 |
| AutoTheta | 0.082573 |
| MSTL_105 | 0.102231 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.903 |
| Excess Kurtosis | -0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.445 |
| Revenue per Share | 0.213 |
| Market Cap | 353,625,152 |
| Forward P/E | -4.72 |
| Beta | 0.95 |
| Website | https://preludetx.com |
As of July 11, 2026, 4:04 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts at strikes significantly below the current price (e.g., $2.50), creating a 'floor' scenario. Conversely, call activity is sparse and concentrated near the money or slightly out-of-the-money, indicating a lack of aggressive bullish conviction despite recent price gains.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.866911 |
| Address1 | 175 Innovation Boulevard |
| All Time High | 95.375 |
| All Time Low | 0.61 |
| Ask | 5.72 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 761,230 |
| Average Daily Volume3 Month | 497,611 |
| Average Volume | 497,611 |
| Average Volume10Days | 761,230 |
| Beta | 0.948 |
| Bid | 3.4 |
| Bid Size | 2 |
| Book Value | 0.729 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.44 |
| Current Ratio | 2.028 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.73 |
| Day Low | 4.45 |
| Debt To Equity | 29.445 |
| Earnings Call Timestamp End | 1,762,952,400 |
| Earnings Call Timestamp Start | 1,762,952,400 |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -81,170,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.639 |
| Enterprise To Revenue | 22.519 |
| Enterprise Value | 376,515,072 |
| Eps Current Year | -0.95 |
| Eps Forward | -0.94 |
| Eps Trailing Twelve Months | -1.0 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4435 |
| Fifty Day Average Change | -0.0034999847 |
| Fifty Day Average Change Percent | -0.0007876639 |
| Fifty Two Week Change Percent | 486.6911 |
| Fifty Two Week High | 5.69 |
| Fifty Two Week High Change | -1.25 |
| Fifty Two Week High Change Percent | -0.21968365 |
| Fifty Two Week Low | 0.75 |
| Fifty Two Week Low Change | 3.69 |
| Fifty Two Week Low Change Percent | 4.92 |
| Fifty Two Week Range | 0.75 - 5.69 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,040,600,000 |
| Float Shares | 27,591,179 |
| Forward Eps | -0.94 |
| Forward P E | -4.7234044 |
| Free Cashflow | -17,930,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 16,720,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13796 |
| Held Percent Institutions | 0.64519995 |
| Implied Shares Outstanding | 79,645,307 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-09-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. |
| Long Name | Prelude Therapeutics Incorporated |
| Market | us_market |
| Market Cap | 353,625,152 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_373775974 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -77,798,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 382,695,699 |
| Number Of Analyst Opinions | 3 |
| Open | 4.73 |
| Operating Cashflow | -43,756,000 |
| Operating Margins | -3.0954099 |
| Payout Ratio | 0.0 |
| Phone | 302 467 1280 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.9009 |
| Post Market Price | 4.4 |
| Post Market Time | 1,783,975,001 |
| Previous Close | 4.805 |
| Price Eps Current Year | -4.673684 |
| Price Hint | 4 |
| Price To Book | 6.090535 |
| Price To Sales Trailing12 Months | 21.14983 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.955 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.365 |
| Regular Market Change Percent | -7.59625 |
| Regular Market Day High | 4.73 |
| Regular Market Day Low | 4.45 |
| Regular Market Day Range | 4.45 - 4.73 |
| Regular Market Open | 4.73 |
| Regular Market Previous Close | 4.805 |
| Regular Market Price | 4.44 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 320,560 |
| Return On Assets | -0.39688 |
| Return On Equity | -0.95247 |
| Revenue Per Share | 0.213 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 64,917,172 |
| Shares Percent Shares Out | 0.0354 |
| Shares Short | 2,822,240 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,693,810 |
| Short Name | Prelude Therapeutics Incorporat |
| Short Percent Of Float | 0.1122 |
| Short Ratio | 5.21 |
| Source Interval | 15 |
| State | DE |
| Symbol | PRLD |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 81,554,000 |
| Total Cash Per Share | 0.822 |
| Total Debt | 17,721,000 |
| Total Revenue | 16,720,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.900675 |
| Two Hundred Day Average Change | 1.539325 |
| Two Hundred Day Average Change Percent | 0.5306782 |
| Type Disp | Equity |
| Volume | 320,560 |
| Website | https://preludetx.com |
| Zip | 19,805 |